I
9.58
-0.52 (-5.15%)
| Previous Close | 10.10 |
| Open | 10.18 |
| Volume | 676,581 |
| Avg. Volume (3M) | 1,396,945 |
| Market Cap | 1,194,204,416 |
| Price / Earnings (TTM) | 479.00 |
| Price / Sales | 1.01 |
| Price / Book | 145.25 |
| 52 Weeks Range | |
| Earnings Date | 24 Apr 2025 |
| Profit Margin | -4.04% |
| Operating Margin (TTM) | 18.73% |
| Diluted EPS (TTM) | 0.020 |
| Quarterly Revenue Growth (YOY) | 2.00% |
| Quarterly Earnings Growth (YOY) | -83.30% |
| Current Ratio (MRQ) | 0.880 |
| Operating Cash Flow (TTM) | 23.00 M |
| Levered Free Cash Flow (TTM) | 158.12 M |
| Return on Assets (TTM) | 10.69% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Indivior PLC | Bearish | - |
AIStockmoo Score
0.1
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.5 |
| Average | 0.13 |
|
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 4.01% |
| % Held by Institutions | 87.25% |
| 52 Weeks Range | ||
| Median | 13.00 (35.70%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 06 Mar 2025 | 13.00 (35.70%) | Buy | 9.89 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Mar 2025 | Announcement | Indivior Announces Further Changes to Board of Directors |
| 27 Feb 2025 | Announcement | Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer |
| 24 Feb 2025 | Announcement | Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection |
| 20 Feb 2025 | Announcement | Indivior Announces FY and Q4 2024 Financial Results |
| 12 Feb 2025 | Announcement | Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |